Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.260
+0.070 (3.20%)
At close: Oct 15, 2026, 4:00 PM EDT
2.230
-0.030 (-1.33%)
After-hours: Oct 15, 2026, 7:33 PM EDT
Ovid Therapeutics Employees
Ovid Therapeutics had 23 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Ovid Therapeutics the 37,978th largest employer in the world and 5,437th in the United States.
Employees
23
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$68,826
Profits / Employee
-$1,499,000
Market Cap
441.37M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 23 | 0 | - |
| Dec 31, 2024 | 23 | -17 | -42.50% |
| Sep 30, 2024 | 25 | -14 | -35.90% |
| Jun 30, 2024 | 40 | 0 | - |
| Mar 31, 2024 | 40 | -6 | -13.04% |
| Dec 31, 2023 | 40 | -4 | -9.09% |
| Sep 30, 2023 | 39 | -5 | -11.36% |
| Jun 30, 2023 | 40 | -4 | -9.09% |
| Mar 31, 2023 | 46 | -3 | -6.12% |
| Dec 31, 2022 | 44 | -13 | -22.81% |
| Sep 30, 2022 | 44 | -1 | -2.22% |
| Jun 30, 2022 | 44 | -16 | -26.67% |
| Mar 31, 2022 | 49 | -15 | -23.44% |
| Dec 31, 2021 | 57 | -10 | -14.93% |
| Sep 30, 2021 | 45 | -20 | -30.77% |
| Jun 30, 2021 | 60 | 0 | - |
| Mar 31, 2021 | 64 | -1 | -1.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Arvinas | 246 |
| Allogene Therapeutics | 152 |
| MapLight Therapeutics | 133 |
| Neurogene | 131 |
| Assembly Biosciences | 73 |
| AgomAb Therapeutics NV | 62 |
| Oculis Holding AG | 60 |
OVID News
- 17 hours ago - Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer - PRNewsWire
- 18 hours ago - Ovid Therapeutics initiated with an Outperform at Wolfe Research - TheFly
- 6 days ago - Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 6 days ago - Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald - TheFly
- 9 days ago - Ovid Therapeutics management to meet with B. Riley - TheFly
- 10 days ago - Guggenheim starts Ovid Therapeutics with a Buy on OV329 potential - TheFly
- 10 days ago - Ovid Therapeutics initiated with a Buy at Guggenheim - TheFly
- 4 weeks ago - Ovid Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts